Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20683057 | 0.96 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL26073271 | 0.96 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL3304298 | 0.92 | CA1 (0.44) | TAS1R3TAS1R1TAS1R2ESR1ESR2 | |
| SCHEMBL2804784 | 0.90 | TRPV1 (0.50) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL21183420 | 0.88 | LMNA (0.51) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL30444207 | 0.86 | KMT2A (0.47) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL16809869 | 0.86 | KMT2A (0.47) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL3534933 | 0.85 | ALDH1A1 (0.52) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL3534929 | 0.85 | ALDH1A1 (0.52) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL1724065 | 0.84 | MEN1 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | TAS1R3 4781/4885TAS1R1 4789/4885TAS1R2 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.